Epocrine
Instructions for use:
- 1. Pharmacological action
- 2. Release form
- 3. Indications for use
- 4. Contraindications
- 5. Instructions for use
- 6. Side effects
- 7. Storage conditions
Prices in online pharmacies:
from 7432 rub.
Buy
Epocrin is a drug of the glycoprotein group.
Pharmacological action of Epocrine
Epocrine is a recombinant erythropoietin whose action is to stimulate erythropoiesis.
It is able to activate mitosis and maturation of erythrocytes from progenitor cells. Recombinant epoetin type alpha is synthesized in mammalian cells that contain a gene that can code for human erythropoietin.
The composition of mammalian epoetin, as well as its immunological and biological properties, is similar to that of human erythropoietin.
With the introduction of epoetin alfa into the human body, the level of hematocrit and hemoglobin increases, the blood supply to tissues and the work of the heart improve.
The greatest efficacy of the drug is noted in those types of anemias that are caused by chronic renal failure.
In rare cases, long-term use of epoetin in the treatment of anemias can lead to the formation of neutralizing antibodies to human erythropoietin, and sometimes partial red cell aplasia develops.
Release form
According to the instructions for Epocrine, the drug is produced in the form of an injection solution, which can have a different content of active substance: 1000, 4000, 2000 or 10000 IU. The solution is a colorless liquid, packed in ampoules, of which 10 pieces are contained in one pack.
Indications for use of Epocrine
Epocrine is recommended for use in the following cases:
- with anemia in patients with chronic renal failure (including those on hemodialysis);
- as a prophylaxis and for the treatment of anemia after prolonged anticancer therapy;
- for the prevention and treatment of anemia caused by the use of zidovudine in patients infected with HIV;
- as a prophylaxis and in the treatment of anemia in patients with diagnosed myeloma, with non-Hodgkin's lymphomas, the grade of malignancy of which is defined as "low", with rheumatoid arthritis and chronic lymphocytic leukemia;
- for the prevention and treatment of anemia in premature babies born with a body weight of less than 1500 g;
- in order to reduce the volume of blood transfused during acute blood loss and surgery.
Contraindications
Epocrine has a number of contraindications, the instruction to Epocrine recommends that you familiarize yourself with them before starting the medication. Epocrine should not be used in the following cases:
- with partial red cell aplasia, if therapy with erythropoietin has already been carried out;
- with uncontrolled arterial hypertension;
- if it is impossible to carry out adequate anticoagulant treatment;
- during the period within a month after myocardial infarction;
- with unstable angina pectoris;
- with an increased risk of thromboembolism and deep vein thrombosis;
- with porphyria;
- with hypersensitivity to any of the components of Epocrine.
Epocrin is prescribed with caution to the following groups of patients:
- patients with various malignant neoplasms;
- patients with thrombosis (including a history);
- patients with sickle cell anemia;
- patients with epilepsy;
- patients with chronic liver failure;
- patients with moderate anemia without iron deficiency.
Instructions for use of Epocrine
Epocrine is administered subcutaneously or intravenously in the treatment of anemia in patients with chronic renal failure. Changing the route of administration requires dose adjustment only if necessary (it should be noted that to achieve the same therapeutic effect with subcutaneous administration, 20-30% less drug is required than with intravenous administration). The optimal hemoglobin (HB) content in the blood of patients with anemia in chronic renal failure: in adults - from 100 to 120 g / l, in children - from 95 to 110 g / l.
Epocrine treatment is divided into two stages:
- the stage of correction, at which the initial dose of Epocrine for subcutaneous administration is 30 IU / kg three times a week (for intravenous administration - 50 IU / kg with the same frequency). This phase lasts until the optimal HB concentration is reached. Control should be done weekly. In this case, situations are possible: a) with an increase in hematocrit from 0.5 to 1% within a week - the dose is not changed; b) hematocrit grows by less than 0.5% per week - increase the dose by 1.5 r; c) the rate of increase is more than 1% over the same period - reduce the dose by 1.5 r; d) hematocrit does not change or decreases - an analysis of the causes of resistance is needed;
- maintenance therapy stage. The hematocrit should be kept at the level of 30-35%, for this, the dose of Epocrine used at the correction stage is reduced by 1.5 times. After that, the maintenance dose of Epocrine is selected taking into account the individual dynamics of hemoglobin and hematocrit. Stabilization of hematological parameters makes it possible to prescribe the introduction of Epocrine once every 1-2 weeks.
The initial and final dosage of Epocrine is determined in accordance with the disease, condition and age of the patient:
- before starting treatment and prevention of anemia with Epocrine in patients with solid tumors, the level of endogenous erythropoietin should be determined. If it is less than 200 IU / ml, the initial dose for intravenous administration should be 150 IU / kg (for subcutaneous administration - 100 IU / kg). The dose may be increased to 300 IU / kg (maximum) in the absence of a response;
- in the treatment and as a prophylaxis of anemia associated with the use of zidovudine in HIV-positive patients, intravenous administration of Epocrine in an amount of 100-150 IU / kg is recommended only if the dose of zidovudine is not more than 4.2 g per week, and the level of endogenous erythropoietin does not exceed 500 IU / ml;
- prevention and treatment of anemia in patients with rheumatoid arthritis is carried out with Epocrine s / c at a dosage of 50-75 IU / kg three times a week. Then, if the HB content increases by less than 10 g / l, the dose can be increased to 150-200 IU / kg (maximum), the frequency remains the same;
- prevention and treatment of anemia in children with low birth weight: the dosage is 200 IU / kg body weight three times a week. It is necessary to start from the 6th day of life and until normal hematocrit and hemoglobin values are reached, but no longer than 6 weeks;
- prevention of anemia in acute blood loss and operations is carried out by intravenous or subcutaneous administration of Epocrin in an amount of 100 to 150 IU / kg. With the normalization of hemolytic parameters, therapy is canceled.
Side effects of Epocrine
You should carefully read the instructions for Epocrine, since the use of the drug can cause the appearance of adverse reactions, among them:
- drowsiness, dizziness, headache, arthralgia, myalgia;
- worsening of the course of arterial hypertension, hypertensive crisis;
- hyperkalemia, hyperphosphatemia, decreased serum ferritin;
- hyperemia, burning, soreness at the injection site;
- itching, hives, eczema;
- thrombocytosis, exacerbation of porphyria, respiratory failure and blood pressure.
Storage conditions
Store Epocrine at temperatures between 2 and 8 ° C for no more than 2 years.
Epocrine: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Epocrin 4000 IU solution for intravenous and subcutaneous administration 1 ml 10 pcs. RUB 7432 Buy |
|
Epocrin 10000 IU solution for intravenous and subcutaneous administration 1 ml 10 pcs. RUB 17930 Buy |
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
